Discover the top 28 companies transforming the oligonucleotide synthesis market, including Danaher Corporation, Thermo Fisher Scientific Inc., Merck KGaA, and other industry leaders. Backed by a market projected to grow from $8.9B to $24.7B by 2030 at a CAGR of 18.6%, this analysis highlights competitive strengths, breakthrough innovations, and strategic moves shaping the future of the industry. Access the full market research report for deeper insights.
Download PDF Brochure:“Click Here”
Spotlights on the Industry’s Top Oligonucleotide Synthesis Companies
Danaher Corporation
Danaher Corporation is a global science and technology innovator that maintains a commanding presence in the oligonucleotide synthesis market primarily through its subsidiary brands, including Integrated DNA Technologies (IDT). The company provides a comprehensive suite of life sciences tools and advanced synthesis technologies, focusing on high-throughput and custom genomic solutions. Recent strategic expansions, such as IDT opening a new manufacturing facility in Iowa in 2024, underscore Danaher’s commitment to scaling production for clinical-grade oligonucleotides and CRISPR guide RNAs.
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific is a market leader with a 21% share, offering an extensive portfolio that encompasses oligonucleotide synthesis equipment, reagents, and diagnostic assays. The company is recognized for its robust infrastructure and ability to support the entire workflow from research to commercial-scale manufacturing. Its position is bolstered by a strong global distribution network and a focus on high-purity products essential for the growing demand in molecular biology and genomic research.
Merck KGaA
Merck KGaA is a major player in the field, leveraging its solid infrastructure and extensive expertise in drug development to provide specialized oligonucleotide synthesis solutions. The company is well-positioned to address the potential of nucleic acid-based drugs, particularly in therapeutic areas where conventional treatments have failed. Merck’s offerings are integrated into its broader life sciences segment, providing critical materials and services for both academic research and large-scale pharmaceutical manufacturing.
LGC Limited
LGC Limited, specifically through its Biosearch Technologies brand, is a key provider of genomic tools and services. The company specializes in high-quality oligonucleotide synthesis for diagnostics and research, recently launching novel fluorescently labeled oligos for digital PCR-based applications. LGC’s presence is characterized by its focus on precision genomics and its ability to support advanced mRNA therapeutics and vaccine development through specialized modification services.
Eurofins Scientific
Eurofins Scientific is a global leader in nucleic acid services, recognized for its high-quality oligonucleotide synthesis applications and extensive diagnostic network. The company provides custom synthesis, modification, and purification services to support a wide range of industries, including biotechnology and academic research. Recent enhancements to its oligo modification services further demonstrate Eurofins’ commitment to supporting the evolving needs of the mRNA therapeutics and vaccine markets.
Agilent Technologies, Inc.
Agilent Technologies is a standout provider of state-of-the-art instruments and integrated solutions, consistently ranked among the top companies in the oligonucleotide synthesis sector. The company’s portfolio includes high-precision synthesizers and advanced analytical systems used in research, diagnostics, and therapeutics. Agilent has actively expanded its production capacity for therapeutic nucleic acids, including a multi-line investment at its Frederick, Colorado facility to meet rising market demand.
Kaneka Corporation
Kaneka Corporation, largely through its partnership with Eurogentec, is a significant contributor to the global and European oligonucleotide markets. The company provides a range of services from research and development to large-scale GMP commercial production, specializing in mRNA synthesis and complex oligonucleotide manufacturing. Its focus on regulatory compliance and high-capacity production, such as its mRNA synthesis facility in Belgium, makes it a preferred partner for international pharmaceutical clients.
Maravai LifeSciences
Maravai LifeSciences, through its subsidiary TriLink BioTechnologies, is a critical supplier in the oligonucleotide market, particularly known for its expertise in modified nucleic acids and mRNA capping technologies. The company plays a vital role in supporting the development of next-generation therapeutics and vaccines by providing high-purity reagents and custom synthesis services. Maravai is strategically positioned to capitalize on the increasing shift toward large-scale synthesis for clinical and commercial-stage drugs.
Azenta US Inc.
Azenta Life Sciences provides specialized genomic services that contribute to the oligonucleotide synthesis ecosystem. The company focuses on supporting the life sciences industry with reliable sample management and genomic workflows, which includes the utilization of synthesized oligonucleotides for research and diagnostic applications. Azenta is recognized for its role in enabling pharmaceutical and biotechnology firms to scale their genomic research and development efforts.
Twist Bioscience
Twist Bioscience is a pioneer in using silicon-based technology to manufacture synthetic DNA at a high scale and low cost. In the oligonucleotide synthesis market, Twist is known for its high-throughput platform that produces large volumes of high-quality oligos for applications such as NGS target enrichment, gene synthesis, and drug discovery. The company’s innovative approach allows for rapid turnaround times and precision, making it a key disruptor in the synthetic biology space.
GenScript
GenScript Biotech is a leading global biotechnology company that has significantly expanded its oligonucleotide synthesis capabilities for therapeutic and research applications. In 2023, the company increased the size of its principal manufacturing plant in China to scale the production of oligonucleotides and peptides. GenScript offers a diverse range of custom solutions, including large-scale manufacturing and specialized modification services, catering to a global client base in the life sciences sector.
Biogen
Biogen is a major biopharmaceutical company that acts as both a consumer and a key player in the oligonucleotide synthesis landscape through its focus on nucleic acid-based therapeutics. The company is heavily involved in the development and commercialization of antisense oligonucleotides (ASOs) for neurological disorders. Biogen’s market presence is defined by its strong product footprint and its role in driving the clinical demand for high-purity, large-scale oligonucleotide production.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the development of RNA interference (RNAi) therapeutics, making it a central figure in the demand side of the oligonucleotide synthesis market. The company’s pipeline of siRNA-based drugs requires sophisticated and high-purity oligonucleotide synthesis to achieve target specificity and therapeutic efficacy. Alnylam’s success in gaining FDA approvals for multiple RNAi products has been a primary driver for innovation and capacity expansion within the broader synthesis industry.
Sarepta Therapeutics, Inc.
Sarepta Therapeutics specializes in the development of RNA-targeted therapies, particularly for rare neuromuscular diseases like Duchenne muscular dystrophy. As a prominent player in the antisense oligonucleotide space, Sarepta relies on advanced synthesis technologies to produce phosphorodiamidate morpholino oligomers (PMOs). The company’s clinical and commercial success significantly contributes to the growth of the specialized oligonucleotide manufacturing and services segment.
AstraZeneca
AstraZeneca is a global pharmaceutical leader that increasingly integrates oligonucleotide-based strategies into its drug discovery and development pipelines. The company explores the use of synthetic DNA and RNA for various therapeutic applications, including cardiovascular and metabolic diseases. AstraZeneca’s involvement in the market is characterized by strategic collaborations with synthesis providers and internal research into next-generation nucleic acid delivery systems.
Astellas Pharma Inc.
Astellas Pharma is a major pharmaceutical company that has expanded its focus into genetic medicines and oligonucleotide-based therapies. Through acquisitions and strategic partnerships, Astellas is building a portfolio that utilizes synthetic oligonucleotides to address unmet medical needs. The company’s presence in the market reflects the broader trend of large pharmaceutical firms diversifying into the nucleic acid therapeutics space to drive long-term growth.
Jazz Pharmaceuticals plc
Jazz Pharmaceuticals is a global biopharmaceutical company that incorporates oligonucleotide research into its specialized medicine portfolio. While traditionally focused on sleep medicine and oncology, the company’s interest in targeted therapies includes the exploration of nucleic acid-based approaches. Jazz Pharmaceuticals contributes to the market as a developer and potential commercializer of innovative therapies that require precision oligonucleotide synthesis.
Nippon Shinyaku, Co. Ltd.
Nippon Shinyaku is a Japanese pharmaceutical company recognized for its contributions to the development of antisense oligonucleotide therapeutics, particularly for rare diseases. The company’s expertise in nucleic acid drug discovery has led to the successful commercialization of specialized oligo-based treatments. Nippon Shinyaku represents a key regional leader in the Asia-Pacific market, driving demand for high-quality, clinical-grade oligonucleotide synthesis.
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals is the pioneer and undisputed leader in antisense oligonucleotide (ASO) therapeutics. With a robust pipeline of over 40 antisense drugs and numerous FDA-approved products, Ionis has defined much of the modern oligonucleotide therapeutics landscape. The company’s business model often involves technology transfers and partnerships with major pharmaceutical firms, making it a primary driver of synthesis technology innovation and manufacturing demand.
Novartis AG
Novartis AG is a global healthcare leader that has established a significant presence in the oligonucleotide synthesis market through the development of RNA-based medicines. The company’s portfolio includes high-profile siRNA therapies, and it continues to invest in advanced nucleic acid platforms. Novartis’s large-scale clinical trials and commercial launches are major factors driving the industry’s shift toward high-capacity, GMP-compliant oligonucleotide manufacturing.
Oligomaker ApS
Oligomaker ApS is a specialized company that manufactures and provides DNA/RNA synthesizers designed for research and commercial laboratories. Their technology focuses on enabling high-quality, cost-effective synthesis with customizable scales, ranging from small research batches to larger production runs. Oligomaker serves as a critical equipment provider, empowering laboratories to maintain internal synthesis capabilities and improve turnaround times.
Biolegio B.V.
Biolegio B.V. is an agile biotechnology company that has distinguished itself as an emerging leader by securing a strong foothold in specialized niche areas of oligonucleotide synthesis. The company provides high-quality custom oligos for various applications, including PCR, sequencing, and diagnostics. Biolegio is recognized for its flexibility, customer-centric approach, and ability to provide specialized modifications that meet the unique requirements of research and diagnostic sectors.
Biolytic Lab Performance, Inc.
Biolytic Lab Performance, Inc. is a leading manufacturer of high-throughput oligonucleotide synthesizers and related laboratory equipment. The company provides innovative hardware solutions that allow for the efficient production of synthetic DNA and RNA at various scales. Biolytic has established itself as an emerging market leader by focusing on the performance and reliability of synthesis instrumentation, serving both academic research and industrial manufacturing facilities.
Biocomma Limited
Biocomma Limited is a specialized manufacturer of filtration and purification products that are essential to the oligonucleotide synthesis process. The company provides columns and reagents used in the solid-phase synthesis and subsequent purification of oligonucleotides. By ensuring high-purity output and process efficiency, Biocomma supports the manufacturing needs of diagnostic and biotechnology companies worldwide.
Revvity
Revvity, formerly part of PerkinElmer, is a global provider of health science solutions that offers products and services supporting the oligonucleotide market. The company’s portfolio includes advanced imaging, detection, and informatics tools used to analyze synthesized oligonucleotides in research and clinical settings. Revvity plays a crucial role in the quality control and application phases of the oligonucleotide lifecycle, particularly in genomics and diagnostics.
Bio-Synthesis, Inc.
Bio-Synthesis, Inc. is recognized as one of the top five oligonucleotide synthesis companies, specializing in high-quality custom synthesis and complex chemical modifications. The company provides a wide range of services, including the production of fluorescently labeled probes, modified backbone oligos, and bioconjugates. Bio-Synthesis is a preferred partner for specialized research and development projects that require deep technical expertise in nucleic acid chemistry.
Creative Biogene
Creative Biogene is a leading biotechnology company that offers a comprehensive range of oligonucleotide synthesis services, including custom DNA, RNA, and LNA synthesis. The company supports academic and industrial research by providing high-purity oligonucleotides for applications such as gene expression analysis, PCR, and NGS. Creative Biogene is known for its diverse service portfolio and its ability to deliver custom solutions for complex genomic research projects.
Reprocell Inc.
Reprocell Inc. is a regenerative medicine and genomic services company that utilizes oligonucleotide synthesis in its research and diagnostic platforms. The company focuses on providing high-quality genomic tools and services, including custom oligo production to support stem cell research and personalized medicine. Reprocell’s presence in the market highlights the intersection of synthetic biology and advanced regenerative therapies.
Download PDF Brochure:“Click Here”
